Fetal Mesenchymal Stem Cells for Osteogenesis Imperfecta Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteogenesis imperfecta lack curative interventions, and existing stem cell transplantation methods for this condition have limited clinical experience and require further studies, necessitating the development of effective human fetal mesenchymal stem cells (FMSCs) that can differentiate into osteoblasts for improved bone formation.
Innovation Solution
A cell culture system for expanding human fetal mesenchymal stem cells (FMSCs) that are non-tumorigenic, adherent without growth factors, and can differentiate into osteoblasts, specifically derived from fetal liver tissue, with a high bone formation capacity, suitable for treating osteogenesis imperfecta, involving methods for isolation, expansion, and release testing to ensure quality parameters are met.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell transplantation is performed to treat osteogenesis imperfecta, then bone formation capacity is improved, but clinical experience is limited and treatment efficacy needs further validation
Solution Approach 1:
The patent performs preliminary characterization and validation of FMSCs in vitro before clinical application, establishing their osteogenic differentiation capacity, surface marker expression profiles, and safety characteristics in advance. This preliminary action reduces the time needed for clinical validation by having key efficacy parameters already demonstrated in controlled laboratory settings.
2Reliability
If fetal liver tissue is used as a source for FMSCs, then bone formation capacity is enhanced, but isolation and expansion processes become more complex
Solution Approach 1:
The patent segments the fetal liver tissue into smaller explants or cellular suspensions to facilitate easier isolation and culture initiation. This segmentation approach simplifies the overall process by breaking down the complex tissue structure into manageable units that can be more easily processed and expanded in culture.
Solution Approach 2:
The patent uses intermediary culture conditions and intermediate culture vessels to bridge the gap between tissue isolation and final cell expansion. Specialized culture media and intermediate culture steps serve as mediators that facilitate the transition from complex tissue to expanded cell populations, reducing overall process complexity.
3Reliability
If FMSCs are cultured without growth factors, then cell purity and non-tumorigenicity are maintained, but expansion efficiency may be reduced
Solution Approach 1:
The patent employs self-service culture conditions where FMSCs are cultured without exogenous growth factors, allowing the cells to maintain their natural growth regulation mechanisms. This self-service approach ensures cell purity and prevents transformation while the cells' intrinsic properties drive their expansion, balancing safety with productivity.
Data Source
AI summary
The present invention relates to a population of fetal mesenchymal stem cells (FMSCs). More specifically the present invention relates to FMSCs capable of differentiating into osteoblasts, as well as methods and uses thereof.